Brain Implants Market to hit USD 10 billion by 2032, says Global Market Insights Inc.
September 10, 2023 19:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Brain Implants Market size is expected to be worth USD 10 billion by 2032. The growing burden of neurological disorders along with the...
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
August 28, 2023 07:00 ET
|
PHARMA TWO B LTD
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated with P2B001 showed consistently greater symptomatic control...
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
August 22, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has...
Deep Brain Stimulation Market worth $1.15 Billion by 2030 - Exclusive Report by The Insight Partners
August 16, 2023 08:37 ET
|
The Insight Partners
Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Deep brain stimulator (DBS) is a device comprising a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation via...
RaceTrac’s Run For Research 5K Returns to Truist Park September 16
August 03, 2023 14:00 ET
|
Racetrac, Inc.
ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- According to The Michael J. Fox Foundation for Parkinson’s Research (MJFF), six million people worldwide live with Parkinson’s disease. One million of...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
June 28, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Nature Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson’s Disease
May 15, 2023 13:30 ET
|
Clinical Ink
Winston Salem, NC, May 15, 2023 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, announces the publication of “Using a smartwatch and smartphone to assess early...
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
April 25, 2023 09:07 ET
|
ZyVersa Therapeutics
Parkinson’s disease (“PD”), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular...
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
April 23, 2023 08:30 ET
|
PHARMA TWO B LTD
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly...
Neuronascent Announces the Expansion of its Board of Directors
April 12, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...